Prediction of inclisiran efficacy in patients with established atherosclerotic cardiovascular disease: the SIRIUS in-silico modelling of cardiovascular outcomes - Takeaways - MDSpire

Prediction of inclisiran efficacy in patients with established atherosclerotic cardiovascular disease: the SIRIUS in-silico modelling of cardiovascular outcomes

  • By

  • Denis Angoulvant

  • Emmanuel Peyronnet

  • Bertrand Cariou

  • Pierre Amarenco

  • Franck Boccara

  • Jean-Pierre Boissel

  • Alexandre Bastien

  • Eulalie Courcelles

  • Alizée Diatchenko

  • Anne Filipovics

  • Solène Granjeon-Noriot

  • Riad Kahoul

  • Guillaume Mahé

  • Lolita Portal

  • Solène Porte

  • Yishu Wang

  • Emmanuelle Bechet

  • Philippe Gabriel Steg

  • December 26, 2025

  • 0 min

Share

  • 1

    Inclisiran significantly reduces LDL-C by 49.7% compared to placebo in patients with established atherosclerotic cardiovascular disease.

  • 2

    The SIRIUS in-silico model predicts a 25.2% reduction in the risk of 3-point major adverse cardiovascular events with inclisiran.

  • 3

    Inclisiran is expected to lower the risk of myocardial infarction by 34.8% and ischaemic stroke by 26% compared to placebo.

  • 4

    The simulation predicts a 7.1% relative reduction in cardiovascular death risk among patients treated with inclisiran.

  • 5

    SIRIUS is the first in-silico simulation to model the cardiovascular outcomes of lipid-lowering therapy in a virtual ASCVD population.

Original Source(s)

Related Content